Literature DB >> 6427791

Inhibition of thromboxane synthetase by OKY-1581 stimulates the formation of PGE2, PGF2 alpha, PGD2 and 6-keto-PGF1 alpha in human platelets.

P Uotila, M Matintalo.   

Abstract

When intact human platelets were incubated with 200 microM 14C-arachidonic acid the formation of TXB2 and HHT was inhibited dose dependently by OKY-1581. The IC50 for the formation of TXB2 was 60 nM and for HHT 90 nM. The amounts of PGE2, PGF2 alpha, PGD2 and 6-keto- PGF1 alpha were correspondingly increased. The combined amount of all cyclo-oxygenase metabolites (TXB2, HHT and prostaglandins) was not changed by OKY-1581 (1 nM - 10 microM). The formation of the lipoxygenase metabolite, 12-HETE, was also not changed by OKY-1581. The present study indicates that the inhibition of thromboxane synthetase in human platelets will direct arachidonate metabolism via the cyclo-oxygenase pathway mainly to PGE2, PGF2 alpha and PGD2 and to a smaller extent to PGI2.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6427791     DOI: 10.1016/0262-1746(84)90022-2

Source DB:  PubMed          Journal:  Prostaglandins Leukot Med        ISSN: 0262-1746


  2 in total

1.  ZD1542, a potent thromboxane A2 synthase inhibitor and receptor antagonist in vitro.

Authors:  R P Brownlie; N J Brownrigg; H M Butcher; R Garcia; R Jessup; V J Lee; S Tunstall; M G Wayne
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

2.  Profiling the eicosanoid networks that underlie the anti- and pro-thrombotic effects of aspirin.

Authors:  Marilena Crescente; Paul C Armstrong; Nicholas S Kirkby; Matthew L Edin; Melissa V Chan; Fred B Lih; Jing Jiao; Tania Maffucci; Harriet E Allan; Charles A Mein; Carles Gaston-Massuet; Graeme S Cottrell; Jane A Mitchell; Darryl C Zeldin; Harvey R Herschman; Timothy D Warner
Journal:  FASEB J       Date:  2020-06-27       Impact factor: 5.834

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.